Purpose: According to current guidelines, molecular tests predicting the outcome of breast
cancer patients can be used to assist in making treatment decisions after consideration of …

Context The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone
receptor–positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and …

Purpose The clinical outcome of tamoxifen-treated breast cancer patients may be influenced
by the activity of cytochrome P450 enzymes that catalyze the formation of antiestrogenic …

Background The cosmopolitan moon jelly Aurelia is characterized by high degrees of
morphological and ecological plasticity, and subsequently by an unclear taxonomic status. The …

The International Tamoxifen Pharmacogenomics Consortium was established to address
the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in …

The question of whether genetic polymorphisms of CYP2D6 can affect treatment outcome in
patients with early postmenopausal breast cancer has been a matter of debate. With the …

Background Adjuvant tamoxifen is a valid treatment option for women with oestrogen receptor
(ER)-positive breast cancer. However, up to 40% of patients experience distant or local …

Purpose: This study aimed to validate matrix-assisted laser desorption/ionization–time-of-flight
mass spectrometry (MALDI-TOF MS)/Taqman copy number assay (CNA) CYP2D6 …

Purpose: Prediction of impaired tamoxifen (TAM) to endoxifen metabolism may be relevant
to improve breast cancer treatment, eg, via TAM dose increase. The polymorphic cytochrome …

Several tumor entities have been reported to overexpress K Ca 3.1 potassium channels due
to epigenetic, transcriptional, or post-translational modifications. By modulating membrane …